SNDX

Syndax Pharmaceuticals Inc

SNDX.US syndax.com
18.18
-0.64 (-3.40%)
USD · NASDAQ
52-week range
12.99
25.59
Trading at 41% of the 52-week range
Market Cap
1.62B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.17
Div. Yield
N/A
% Institutions
126.21%
% Insiders
1.69%

1 Year

+11.1%

3 Year

+5.1%

10 Year

+22.1%
Description

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Company Information

Company Name
Syndax Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US87164F1057
CIK: 0001395937
CUSIP: 87164F105
Currency: USD
Full Time Employees: 298
Phone: 781 419 1400
Website: syndax.com
Fiscal Year End: December
IPO Date: Mar 03, 2016
Description:

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Address:

730 Third Avenue, New York, NY, United States, 10017

People

Directors & Officers

Name Title Year Born
Mr. Michael A. Metzger M.B.A. CEO & Director 1971
Mr. Keith Alan Goldan CPA CFO, Treasurer & Principal Accounting Officer 1971
Mr. Luke J. Albrecht J.D. Senior VP, General Counsel & Secretary 1979
Mr. Steven Closter Chief Commercial Officer 1969
Dr. Nicholas A.J. Botwood B.Sc., MBBS Head of Research & Development and Chief Medical Officer 1968
Dr. Peter Ordentlich B.Sc., Ph.D. Co-Founder & Chief Scientific Officer 1969
Dr. Richard A. Heyman Ph.D. Co-Founder 1957
Dr. Ronald M. Evans Ph.D. Co-Founder, Advisor and Chair of Scientific Advisory Board 1950
Dr. Michael Downes Ph.D. Co-Founder NA
Sharon Klahre Vice President of Investor Relations & Communications NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 09, 2026 Keith A Goldan N/A Sale 3.41K $21.03 $71.71K
Feb 09, 2026 Michael A Metzger N/A Sale 17.16K $21.03 $360.85K
Feb 06, 2026 Keith A Goldan N/A Sale 2.08K $20.62 $42.93K
Feb 06, 2026 Michael A Metzger N/A Sale 7.41K $20.62 $152.84K
Sep 08, 2025 Michael A Metzger N/A Sale 157.31K $16.41 $2.58M
Aug 18, 2025 Dennis Podlesak N/A Sale 19.20K $15.84 $304.13K
Aug 15, 2025 Dennis Podlesak N/A Sale 19.20K $15.54 $298.37K
Jul 16, 2025 Keith A Goldan N/A Sale 1.30K $9.29 $12.04K
Jul 16, 2025 Michael A Metzger N/A Sale 7.53K $9.29 $69.99K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 8.25M Mar 31, 2026 9.24% $0.00 0.19%
Kynam Capital Management, LP 8.05M Jun 30, 2026 9.02% $9.73 0.00%
The Goldman Sachs Group Inc 5.00M Mar 31, 2026 5.60% $0.01 -12.27%
State Street Corp 4.43M Mar 31, 2026 4.96% $0.00 -3.62%
Bank of America Corp 4.25M Mar 31, 2026 4.76% $0.01 -9.78%
Vanguard Capital Management, LLC 3.82M Mar 31, 2026 4.28% $0.00 0.00%
Deerfield Management Co 3.78M Mar 31, 2026 4.23% $1.04 0.00%
Eversept Partners, LP 2.80M Jun 30, 2026 3.13% $3.17 -3.03%
Kingdon Capital Management LLC 2.50M Jun 30, 2026 2.80% $5.60 0.00%
StemPoint Capital LP 2.43M Mar 31, 2026 2.72% $5.48 81.54%
Hood River Capital Management LLC 2.35M Mar 31, 2026 2.64% $0.55 1.63%
Geode Capital Management, LLC 2.16M Mar 31, 2026 2.42% $0.00 3.16%
Franklin Templeton Inc 2.15M Mar 31, 2026 2.41% $0.01 -11.21%
Millennium Management LLC 2.05M Jun 30, 2026 2.30% $0.02 929.43%
Point72 Asset Management, L.P. 1.99M Mar 31, 2026 2.22% $0.06 -59.33%
Elmind Capital LP 1.86M Mar 31, 2026 2.08% $12.30 0.00%
Vanguard Portfolio Management, LLC 1.74M Mar 31, 2026 1.95% $0.00 0.00%
BNP Paribas Investment Partners SA 1.73M Mar 31, 2026 1.94% $0.05 25.94%
Soleus Capital Management, L.P. 1.63M Jun 30, 2026 1.82% $1.23 -5.73%
Two Sigma Investments LLC 1.58M Mar 31, 2026 1.77% $0.03 37.72%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 State Street® SPDR® S&P® Biotech ETF 3.71M 4.16% ▼ 1.06% Aug 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 2.84M 3.18% ▲ 0.53% Jul 31, 2026
3 iShares Russell 2000 ETF 2.28M 2.55% ▼ 0.57% Aug 31, 2026
4 Hood River Small-Cap Growth Instl 1.21M 1.36% ▲ 0.00% Jun 30, 2026
5 Franklin Biotechnology Discv A(acc)USD 1.08M 1.20% ▲ 5.50% Jul 31, 2026
6 BNP Paribas US Small Cap ClassicC 1.07M 1.20% ▲ 6.25% Jul 31, 2026
7 Franklin US Small Cap Growth Equity 1.04M 1.17% ▲ 79.63% Jul 31, 2026
8 Vanguard Institutional Extnd Mkt Idx Tr 1.02M 1.14% ▲ 0.84% Jul 31, 2026
9 Fidelity Small Cap Index 963.60K 1.08% ▲ 12.36% Jun 30, 2026
10 Franklin Small Cap Growth Adv 928.03K 1.04% ▲ 59.62% Jul 31, 2026

Financial Highlights

Market Cap: $1.62B
EBITDA: $-194.16M
PEG Ratio: $0.00
Book Value: $0.17
Earnings/Share: $-2.51
Profit Margin: -87.52%
Operating Margin: -54.95%
ROA (TTM): -18.67%
ROE (TTM): -255.93%
Revenue (TTM): $252.25M
Revenue/Share (TTM): $2.87
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 91.80%

Valuation Metrics

Enterprise Value: $1.72B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 89.30M
Shares Float: 80.30M
% Insiders: 1.69%
% Institutions: 126.21%
Short % Float: 24.70%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$172.35M
Cost of Goods Sold
adjust
$-6.97M
Gross Profit
subtotal
$165.38M
SG&A
adjust
$-179.68M
R&D
adjust
$-258.78M
Operating Income
subtotal
$-273.08M
Other / Non-Operating Items
adjust
$-12.34M
Net Income
subtotal
$-285.42M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SNDX.US!